

SCH 563705

Catalog No: tcsc0833



Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg



Specifications

CAS No:

473728-58-4

Formula:

$C_{23}H_{27}N_3O_5$

Pathway:

GPCR/G Protein;Immunology/Inflammation

Target:

CXCR;CXCR

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 30 mg/mL (70.51 mM)

Observed Molecular Weight:

425.48

Product Description


SCH 563705 is a potent and orally available **CXCR2** and **CXCR1** antagonist, with **IC₅₀**s of 1.3 nM, 7.3 nM and **K_i**s of 1 and 3 nM, respectively.

IC₅₀ & Target: IC₅₀: 1.3 nM (CXCR2), 7.3 nM (CXCR1)^[1], 5.2 nM (Mouse CXCR2)^[2]

K_i: 1 nM (CXCR2), 3 nM (CXCR1)^[1]

In Vitro: SCH 563705 (Compound 16) is a potent and orally available CXCR2 and CXCR1 antagonist, with IC₅₀s of 1.3 nM, 7.3 nM and K_is of 1 and 3 nM, respectively. SCH 563705 shows potent inhibition against both Gro-α and IL-8 induced human neutrophil migration (chemotaxis IC₅₀ = 0.5 nM, against 30 nM of Gro-α; chemotaxis IC₅₀ = 37 nM, against 3 nM of IL-8)^[1]. SCH 563705 potently inhibits mouse CXCR2 (IC₅₀ = 5.2 nM)^[2].

In Vivo: SCH 563705 has good oral pharmacokinetic profiles in rats, mice, monkeys and dogs^[1]. SCH 563705 (50 mg/kg p.o) reduces blood Ly6G⁺ Ly6C⁺ neutrophil frequency and unchanged levels of Ly6GLy6Chi monocytes. SCH563705 (3-30 mg/kg p.o) treatment causes a dosedependent elevation in plasma levels of CXCL1^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!